Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Introduction: We aimed to determine the added value of cerebrospinal fluid (CSF) to clinical and imaging tests to predict progression from mild cognitive impairment (MCI) to any type of dementia. Methods: The risk of progression to dementia was estimated using two logistic regression models based on 250 MCI participants: the first included standard clinical measures (demographic, clinical, and imaging test information) without CSF biomarkers, and the second included standard clinical measures with CSF biomarkers. Results: Adding CSF improved predictive accuracy with 0.11 (scale from 0–1). Of all participants, 136 (54%) had a change in risk score of 0.10 or higher (which was considered clinically relevant), of whom in 101, it was in agreement with their dementia status at follow‐up. Discussion: An individual person's risk of progression from MCI to dementia can be improved by relying on CSF biomarkers in addition to recommended clinical and imaging tests for usual care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures
Steyerberg, E. W., Vickers, A. J., Cook, N. R., Gerds, T., Gonen, M., Obuchowski, N., Pencina, M. J., & Kattan, M. W. (2010) · Epidemiology · doi:10.1097/ede.0b013e3181c30fb2 · Cited by 5,170
Moons, K. G. M., Altman, D. G., Reitsma, J. B., Ioannidis, J. P. A., Macaskill, P., Steyerberg, E. W., Vickers, A. J., Ransohoff, D. F., & Collins, G. S. (2015) · Annals of Internal Medicine · doi:10.7326/m14-0698 · Cited by 5,147 · cited 1×
“Both prediction models were validated by visually assessing the relation between the observed and predicted proportion of progression to dementia [33,34] (see Supplemental Material 2).”
MethodAdvancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationMitchell, A. J., & Shiri‐Feshki, M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01326.x · Cited by 1,659 · cited 1×
“However, generalizability to old age might be limited as the average age was 69 years, and diagnostic performance has been shown to decrease with age [37], and a 40% a priori risk is higher than other observed proportions [38].”
BackgroundWelsh, K. A., Butters, N., Mohs, R. C., Beekly, D., Edland, S., Fillenbaum, G., & Heyman, A. (1994) · Neurology · doi:10.1212/wnl.44.4.609 · Cited by 951
Injury markers predict time to dementia in subjects with MCI and amyloid pathology
van Rossum, I. A., Vos, S. J. B., Burns, L., Knol, D. L., Scheltens, P., Soininen, H., Wahlund, L.-O., Hampel, H., Tsolaki, M., Minthon, L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182704056 · Cited by 136 · cited 1×
“We selected participants with MCI who consecutively attended a memory clinic from a range of cohorts in various European countries: the Development of Screening Guidelines and Clinical Criteria for Predementia AD (DESCRIPA) multicenter study [12] (inclusion between 2003 and 2005, with an additional sample of participa…”
MethodSelf-citationRichard, E., Schmand, B. A., Eikelenboom, P., & Van Gool, W. A. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002541 · Cited by 84 · cited 1×
“Other previous research [6,8] only analyzed CSF in addition to neuropsychological test or CSF in addition to MRI.”
Method
Cited by
Nho, K., Kueider‐Paisley, A., MahmoudianDehkordi, S., Arnold, M., Risacher, S. L., Louie, G., Blach, C., Baillie, R., Han, X., Kastenmüller, G., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.012 · Cited by 343
Shaw, L. M., Arias, J., Blennow, K., Galasko, D., Molinuevo, J. L., Salloway, S., Schindler, S., Carrillo, M. C., Hendrix, J. A., Ross, A., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.220 · Cited by 266
“Studies have begun to look at some of these questions [87,144], but much more work is needed to document the potential impact of CSF AD biomarker testing on clinical outcomes in patients across the spectrum of AD.”
BackgroundSelf-citationAlgorithmic fairness of machine learning models for Alzheimer disease progression
Yuan, C., Linn, K. A., & Hubbard, R. A. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.42203 · Cited by 49
Llano, D. A., Devanarayan, P., & Devanarayan, V. (2019) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000328 · Cited by 35
Metadata
- Authors
- Handels, R. L. H., Vos, S. J. B., Kramberger, M. G., Jelic, V., Blennow, K., van Buchem, M., van der Flier, W., Freund‐Levi, Y., Hampel, H., Olde Rikkert, M., Oleksik, A., Pirtosek, Z., Scheltens, P., Soininen, H., Teunissen, C., Tsolaki, M., Wallin, A. K., Winblad, B., Verhey, F. R. J., & Visser, P. J.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2017-02-16
- Volume
- 13
- Issue
- 8
- Pages
- 903-912
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2587777515
- Cited by
- 41
- References
- 7
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. https://app.cochat.ai/papers/10.1016/j.jalz.2016.12.015
- The paper
- Handels, R. L. H., Vos, S. J. B., Kramberger, M. G., Jelic, V., Blennow, K., van Buchem, M., van der Flier, W., Freund‐Levi, Y., Hampel, H., Olde Rikkert, M., Oleksik, A., Pirtosek, Z., Scheltens, P., Soininen, H., Teunissen, C., Tsolaki, M., Wallin, A. K., Winblad, B., Verhey, F. R. J., & Visser, P. J. (2017). Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2016.12.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.